Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6


PHOX2B is a suppressor of neuroblastoma metastasis.

Naftali O, Maman S, Meshel T, Sagi-Assif O, Ginat R, Witz IP.

Oncotarget. 2016 Mar 1;7(9):10627-37. doi: 10.18632/oncotarget.7056.


Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777. Epub 2015 Jan 5.


A 6-gene signature identifies four molecular subgroups of neuroblastoma.

Abel F, Dalevi D, Nethander M, J├Ârnsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S.

Cancer Cell Int. 2011 Apr 14;11:9. doi: 10.1186/1475-2867-11-9.


Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK; International neuroblastoma Risk Group Task Force.

Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28.


Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Cheung IY, Feng Y, Gerald W, Cheung NK.

Clin Cancer Res. 2008 Nov 1;14(21):7020-7. doi: 10.1158/1078-0432.CCR-08-0541.


Models, mechanisms and clinical evidence for cancer dormancy.

Aguirre-Ghiso JA.

Nat Rev Cancer. 2007 Nov;7(11):834-46. Review.

Supplemental Content

Support Center